Evidence based pathology: Are EGFR tests valid predictors of treatment response to erlotinib or gefitinib in patients with pulmonary adenocarcinoma?

被引：0
|
作者：
Dastane, A. M. [1 ]
Gupta, R. [1 ]
Mckenna, R. J. [1 ]
Marchevsky, A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1548
引用
收藏
页码：340A / 340A
页数：1
相关论文
共 50 条
  • [1] Evidence based pathology: Are EGFR tests valid predictors of treatment response to erlotinib or gefitinib in patients with pulmonary adenocarcinoma?
    Dastane, A. M.
    Gupta, R.
    Mckenna, R. J.
    Marchevsky, A.
    MODERN PATHOLOGY, 2008, 21 : 340A - 340A
  • [2] EGFR kinase domain mutations, but not copy number, predict response to erlotinib and gefitinib in patients with advanced lung adenocarcinoma
    Sholf, L. M.
    Janne, P. A.
    Jackman, D. M.
    Joshi, V. A.
    Lindeman, N. I.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2007, 9 (05): : 692 - 692
  • [3] Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
    Shee, Chai Chee
    Kin, Liam Chong
    Kek, Pang Yong
    Siong, Kow Keng
    Ern, Poh Mau
    Kuan, Wong Chee
    Liang, Tan Jiunn
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [4] EGFR mutation and striking response to gefitinib in a patient with leptomeningeal carcinomatosis and erlotinib-refractory adenocarcinoma lung cancer
    Choong, Nicholas W.
    Dietrich, Sascha
    Seiwert, Tanguy Y.
    Tretiakova, Maria S.
    Nallasura, Vidya
    Davies, Gareth C.
    Lipkowitz, Stanley
    Husain, Aliya N.
    Salgia, Ravi
    Ma, Patrick C.
    CANCER RESEARCH, 2006, 66 (08)
  • [5] Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification
    Wang, Chunguo
    Xu, Feng
    Shen, Jianfei
    Zhang, Linna
    Zhang, Jian
    Jin, Jiang
    Ampolli, Luca
    van Schil, Paul
    Kimura, Hideharu
    Grossi, Francesco
    Suda, Kenichi
    Zhang, Bo
    Ma, Dehua
    JOURNAL OF THORACIC DISEASE, 2018, 10 (11) : E779 - E783
  • [6] Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
    Sim, Sung Hoon
    Han, Sae-Won
    Oh, Do-Youn
    Lee, Se-Hoon
    Kim, Dong-Wan
    Im, Seock-Ah
    Chung, Doo Hyun
    Kim, Tae-You
    Lee, Jong Seok
    Kim, Young Whan
    Heo, Dae Seog
    Bang, Yung-Jue
    LUNG CANCER, 2009, 65 (02) : 204 - 207
  • [7] Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment
    Wu, Wen-Shuo
    Wu, Chieh-Hung
    Lai, Shinn-Liang
    Chiu, Chao-Hua
    Shih, Jen-Fu
    Lee, Yu-Chin
    Chen, Yuh-Min
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (06): : 556 - 562
  • [8] Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation
    Liu, Jing
    Xing, Ligang
    Meng, Xue
    Yue, Jinbo
    Meng, Xiangjiao
    Xie, Peng
    Li, Xiaolin
    Kong, Li
    Yu, Jinming
    ONCOTARGETS AND THERAPY, 2016, 9 : 671 - 679
  • [9] Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Fulton, Linnea E.
    Digumarthy, Subba R.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Sequist, Lecia V.
    ACADEMIC RADIOLOGY, 2016, 23 (03) : 329 - 336
  • [10] EFFICACY OF GEFITINIB AND ERLOTINIB IN INDONESIAN PATIENTS WITH LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
    Asdar, Muhammad Ali
    Syahruddin, Elisna
    Zaini, Jamal
    RESPIROLOGY, 2019, 24 : 55 - 56
12345